Shares of IDEAYA Biosciences Inc. (IDYA) jumped in Monday's premarket session after the company announced some very encouraging news for patients with a rare and tough-to-treat eye cancer. Their experimental drug combination, darovasertib plus crizotinib, posted positive top-line results in a major clinical trial.

For those dealing with metastatic uveal melanoma, this could mean a new and more effective treatment option is on the horizon.

Trial Hits Its Main Goal, and Then Some

IDEAYA is one of those precision medicine oncology shops—they try to find and develop targeted cancer therapies. In this case, their focus paid off. The Phase 2/3 trial for their drug combo met its primary endpoint with flying colors, showing a statistically significant improvement in how long patients lived without their cancer getting worse.

The numbers tell a compelling story. Patients receiving the darovasertib combination had a median progression-free survival (PFS) of 6.9 months. That's more than double the 3.1 months seen in the group that got the investigator's choice of standard therapy. Put another way, the new combo cut the risk of disease progression or death by a substantial 58%.

Secondary Results Are Equally Impressive

If the primary endpoint was a home run, the secondary ones were a grand slam. The trial also looked at overall response rate (ORR)—basically, what percentage of patients saw their tumors shrink. For the darovasertib arm, the ORR was 37.1%. For the standard therapy group, it was just 5.8%.

Even more striking: there were five complete responses—where cancer becomes undetectable—in the darovasertib group. The standard therapy group had zero. For those who did respond to the new combo, the responses lasted a median of 6.8 months.

The data also showed an early, encouraging trend toward improving overall survival, though that will need longer follow-up. On the safety front, the combination was reportedly well-tolerated with a manageable side effect profile.

With these strong results in hand, IDEAYA is moving forward. The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2026.

The Stock's Technical Picture: Strong Run, Mixed Signals

The market's immediate reaction was a massive thumbs-up. But let's look under the hood at the stock's technical indicators, which paint a picture of strong momentum with a few caution flags.

At a recent price of $41.02, the stock is trading well above its key moving averages: 27.7% above its 20-day, 21.8% above its 100-day, and 38.1% above its 200-day simple moving average. That suggests powerful short-term momentum and a solid long-term uptrend.

The 12-month performance of 78.26% and trading near a 52-week high of $41.02 certainly reflect bullish investor sentiment.

However, not every indicator is flashing green. The Relative Strength Index (RSI) sits at 41.52, which is in neutral territory—the stock isn't overbought or oversold. More notably, the Moving Average Convergence Divergence (MACD) is in bearish territory, with the MACD line below the signal line. This can sometimes suggest underlying downward pressure might be building.

Traders are watching key levels. $39.50 is seen as a potential resistance point that could cap upward moves, while $33.00 is viewed as a critical support level where buyers might step back in.

IDYA Stock Price Activity: Reflecting the positive clinical news, IDEAYA Biosciences shares were up 26.36% at $38.60 during premarket trading on Monday, according to market data.